(On Friday, Pfizer Inc. issued a warning that its Cox-2 drug Bextra may increase cardiovascular risk for some patients.)
Meanwhile, the European Medicines Agency in London announced it would review drugs similar to Vioxx.
It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.